The COVID-19 pandemic in Italy: Depressive symptoms immediately before and after the first lockdown.
COVID-19
Depression
PHQ-2
Twin
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
received:
29
07
2021
revised:
14
10
2021
accepted:
23
10
2021
pubmed:
5
11
2021
medline:
15
12
2021
entrez:
4
11
2021
Statut:
ppublish
Résumé
Italy was one of the first countries to be heavily hit by the spread of the new Coronavirus. Longitudinal studies are needed to investigate the real effect of COVID-19 on adult mental health. The Italian Twin Registry carried out a study to investigate, over time, the course of depressive symptoms in the general population. The study relies on data collected just before the beginning (February 2020) and the end (June 2020) of the first lockdown. Symptoms of depression were assessed using the Patient Health Questionnaire, and total scores or categorized depression scores were considered in the analyzes. A total of 1690 adult twins were recruited. The study showed a mean depression score of 1.11 immediately before lockdown and 1.20 immediately after, with an overall prevalence of depressive symptoms increasing from 33.6 to 38.9%. Depressive symptoms immediately after the restriction period were associated with Covid-19 symptoms affecting households, financial problems due to the pandemic and poor social support. Independently of the baseline risk of depressive symptoms, we observed an increased risk among younger and less educated people. Compared to the pre-lockdown period, women and middle-aged people also were found to be at greater risk of developing depressive symptoms. Possible participation bias and residual selection bias. The study shows that the COVID-19 pandemic was associated with an increased depressive symptomatology and that, in such health emergency times, the most vulnerable persons are young adults, women, and those living in a socially, culturally, or economically disadvantaged environment.
Sections du résumé
BACKGROUND
Italy was one of the first countries to be heavily hit by the spread of the new Coronavirus. Longitudinal studies are needed to investigate the real effect of COVID-19 on adult mental health. The Italian Twin Registry carried out a study to investigate, over time, the course of depressive symptoms in the general population.
METHODS
The study relies on data collected just before the beginning (February 2020) and the end (June 2020) of the first lockdown. Symptoms of depression were assessed using the Patient Health Questionnaire, and total scores or categorized depression scores were considered in the analyzes.
RESULTS
A total of 1690 adult twins were recruited. The study showed a mean depression score of 1.11 immediately before lockdown and 1.20 immediately after, with an overall prevalence of depressive symptoms increasing from 33.6 to 38.9%. Depressive symptoms immediately after the restriction period were associated with Covid-19 symptoms affecting households, financial problems due to the pandemic and poor social support. Independently of the baseline risk of depressive symptoms, we observed an increased risk among younger and less educated people. Compared to the pre-lockdown period, women and middle-aged people also were found to be at greater risk of developing depressive symptoms.
LIMITATIONS
Possible participation bias and residual selection bias.
CONCLUSIONS
The study shows that the COVID-19 pandemic was associated with an increased depressive symptomatology and that, in such health emergency times, the most vulnerable persons are young adults, women, and those living in a socially, culturally, or economically disadvantaged environment.
Identifiants
pubmed: 34732338
pii: S0165-0327(21)01208-8
doi: 10.1016/j.jad.2021.10.129
pmc: PMC8557388
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-208Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
Int J Environ Res Public Health. 2020 May 02;17(9):
pubmed: 32370116
J Affect Disord. 2020 Dec 1;277:842-849
pubmed: 33065825
Br J Health Psychol. 2020 Nov;25(4):865-874
pubmed: 32415914
Psychiatry Res. 2020 Aug;290:113108
pubmed: 32450409
Asian J Psychiatr. 2020 Jun;51:102092
pubmed: 32315963
Int J Environ Res Public Health. 2021 Feb 16;18(4):
pubmed: 33669453
J Affect Disord. 2021 Jan 1;278:131-135
pubmed: 32956962
Gen Psychiatr. 2020 Mar 6;33(2):e100213
pubmed: 32215365
JAMA. 2020 Jun 9;323(22):2290-2300
pubmed: 32515813
Twin Res Hum Genet. 2019 Dec;22(6):572-578
pubmed: 31554534
J Occup Environ Med. 2021 Sep 1;63(9):e571-e579
pubmed: 34091576
PLoS One. 2021 Jan 7;16(1):e0245057
pubmed: 33411843
J Psychosom Res. 2020 Sep;136:110186
pubmed: 32682159
BMC Psychol. 2018 Jul 17;6(1):31
pubmed: 30016997
Cad Saude Publica. 2020 Apr 30;36(4):e00054020
pubmed: 32374806
Soc Psychiatry Psychiatr Epidemiol. 2006 Jun;41(6):444-51
pubmed: 16572275
Lancet Psychiatry. 2021 Jul;8(7):610-619
pubmed: 33965057
Int J Environ Res Public Health. 2020 Jul 08;17(14):
pubmed: 32650522
J Gen Intern Med. 2020 Aug;35(8):2296-2303
pubmed: 32472486
J Affect Disord. 2021 Sep 1;292:398-404
pubmed: 34139414
J Epidemiol. 2020 Nov 5;30(11):522-528
pubmed: 32963212
Eur Arch Psychiatry Clin Neurosci. 2016 Mar;266(2):89-124
pubmed: 26874960
Int J Environ Res Public Health. 2020 Mar 31;17(7):
pubmed: 32244498
Front Psychiatry. 2020 Aug 07;11:790
pubmed: 32848952
Psychol Med. 2018 Jun;48(8):1308-1315
pubmed: 29021005
Am J Cardiol. 2017 May 15;119(10):1680-1686
pubmed: 28343600
Am Psychol. 2020 Jul-Aug;75(5):618-630
pubmed: 32496074
Lancet Psychiatry. 2021 Feb;8(2):141-149
pubmed: 33308420
PLoS One. 2020 May 14;15(5):e0233410
pubmed: 32407409
Twin Res. 2001 Dec;4(6):464-77
pubmed: 11780939
Front Psychiatry. 2020 Nov 02;11:559266
pubmed: 33240119
Psychiatry Res. 2020 May;287:112934
pubmed: 32229390
PLoS One. 2020 Apr 16;15(4):e0231924
pubmed: 32298385
Psychiatry Res. 2020 Jun;288:112954
pubmed: 32325383
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Brain Behav Immun. 2020 Jul;87:172-176
pubmed: 32405150
Psychol Med. 2020 Nov 13;:1-10
pubmed: 33183370
BMJ Open. 2021 Jan 12;11(1):e042871
pubmed: 33436472
BMC Public Health. 2020 Nov 4;20(1):1648
pubmed: 33148202
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
J Psychiatr Res. 2021 Apr;136:603-609
pubmed: 33138985
Int J Soc Psychiatry. 2020 Aug;66(5):504-511
pubmed: 32380879
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA. 2020 Jul 7;324(1):93-94
pubmed: 32492088
Eur Psychiatry. 2020 Sep 28;63(1):e87
pubmed: 32981568
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Asian J Psychiatr. 2020 Jun;51:102076
pubmed: 32334409
Psychol Med. 2021 Jan;51(2):201-211
pubmed: 33436130
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110236
pubmed: 33373680
Med Sci Monit. 2020 Apr 26;26:e924609
pubmed: 32335579